Needham Maintains Buy on Phathom Pharmaceuticals, Raises Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reaffirmed a Buy rating on Phathom Pharmaceuticals (NASDAQ:PHAT) and increased the price target from $23 to $26.
January 05, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Joseph Stringer maintains a Buy rating on Phathom Pharmaceuticals and raises the price target from $23 to $26.
The increase in price target by a reputable analyst typically signals a positive outlook on the company's future performance, which can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100